Skip to content

A randomized, controlled, open label, multicenter study on the clinical efficacy of lower limb functional rehabilitation assessment and training in patients with Parkinson's disease

A randomized, controlled, open label, multicenter study on the clinical efficacy of lower limb functional rehabilitation assessment and training in patients with Parkinson's disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500096525
Enrollment
Unknown
Registered
2025-01-24
Start date
2025-02-06
Completion date
Unknown
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

Experimental group:Using a limb function rehabilitation assessment and training system for home gait training
Control group:Perform routine home gait training, including step training, step training, etc

Sponsors

The First Affiliated Hospital,Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosed with primary Parkinson's disease according to the "Diagnostic Criteria for Parkinson's Disease in China (2016 Edition)", and with a Mini Mental State Examination (MMSE) score greater than 18 points; 2. The severity of the disease is classified into stages 2-4 according to the revised HOEHN-YAHR (H&Y) staging system; 3. Ability to walk independently for at least 6 minutes; 4. Meet one of the following conditions: (1) The score for item 10 of the MDS-UPDRS-III Unified Parkinson's Disease Rating Scale is = 2, or (2) The total score for items 9 to 13 of the MDS-UPDRS-III Unified Parkinson's Disease Rating Scale is >= 3, or (3) The walking distance in the 6-minute walk test (6MWT) is <= 360m; 5. Age range: 18-75 years old; 6. Ensure stable drug dosage 30 days before and during clinical trials; 7. Women of childbearing age can ensure the use of sufficient and effective contraceptive measures during clinical trials; 8. Voluntarily participate in the experiment and provide a signed informed consent form;

Exclusion criteria

Exclusion criteria: 1. Parkinson's syndrome caused by cerebrovascular disease, traumatic brain injury, intracranial inflammation, intracranial space occupying lesions, hydrocephalus, medication, or other neurological disorders; 2. Parkinson's disease superimposed syndrome (multiple system atrophy, progressive supranuclear paralysis, cortical basal ganglia degeneration, Lewy body dementia, etc.); 3. Parkinson's disease complicated with various mental illnesses; 4. Suffering from other neuromuscular, bone and joint diseases and lower limb vascular disorders that affect walking ability; 5. Suffering from underlying diseases such as severe heart disease, lung disease, etc. that affect exercise ability; 6. Factors that affect participation in clinical research, such as severe hearing impairment, severe visual impairment, and severe dizziness; 7. Postural hypotension (blood pressure drop >= 20/10mmHg within 3 minutes of standing) or baseline blood pressure below 90/60mmHg after standing for 3 minutes; 8. Pregnant or lactating women; 9. Parkinson's disease patients who have undergone neurosurgery such as deep brain stimulation (DBS) surgery;

Design outcomes

Primary

MeasureTime frame
6-minute walking test (6MWT) walking distance;

Secondary

MeasureTime frame
The average step size of the 6-minute walking test (6MWT);Time for TUG single task testing;Time for TUG cognitive dual task test;Time for single leg standing test;FOG-Q rating;MDS-UPDRS-III rating;Safety evaluation of experimental equipment;Adverse event incidence rate;

Countries

China

Contacts

Public ContactJinsheng Zeng

The First Affiliated Hospital,Sun Yat-sen University

zengjs@pub.guangzhou.gd.cn+86 13322800657

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026